Epizyme's Multiple Myeloma Drug Candidate Inhibits Tumors In Animal Models

Epizyme Inc EPZM has reported positive data from mouse studies for potential first-in-class therapy, EPZ-719, that targets the enzyme SETD2.
The chromosomal abnormality is responsible for about 15% to 20% of multiple myeloma cases and is associated with poor patient prognosis.
Data were presented at the European Hematology Association virtual congress.
Epizyme tested EPZ-719 in mice bearing myeloma tumors with the mutation. The drug safely induced strong tumor growth inhibition of up to 95%.
Tumor regressions were observed in mice that got the drug at the top three doses tested.
The investigators also reported anti-tumor effects in two mouse models of myeloma without the mutation. The drug produced maximum tumor growth inhibition of 79% in one type and 92% in the other at a high dose.
Price Action: EPZM shares are up 2.99% at $8.79 during the market session on the last check Monday.